- Revenue climbed 52% year-over-year to
$2.6 million in Q3 2026, the highest quarterly revenue in the Company's history. - Earnings per share (EPS) swung to
$0.02 in Q3 2026, compared with a loss of$(0.02) in Q3 2025. - Gross margin reached a Company record of 46.3% in Q3 2026, up 1,340 basis points from 32.9% in Q3 2025.
- EBITDA turned positive at
$301,725 in Q3 2026, a$520,326 improvement from a loss of$(218,601) in Q3 2025.
Q3 2026 Financial Highlights
Revenue for the quarter ended
With revenue growing faster than costs, gross margin widened by approximately 1,340 basis points to 46.3%, up from 32.9% a year earlier. The result sets a new Company record, surpassing the previous high of 44.5% achieved just last quarter.
EPS rose to
EBITDA improved by
Year-to-date results reinforce the strength of the business. For the nine months ended
2026 Financial Outlook
With three consecutive profitable quarters now behind us,
Recent Operational Highlights
Syra Health continues to grow its work with managed care organizations (MCOs) serving hundreds of thousands of Medicaid members, including large-scale engagements that span:- Population health implementations that collect, analyze, and report on claims data
- A live-agent call center focused on improving quality measures and closing care gaps
- Process design for expedited credentialing and recredentialing of Medicaid providers
- Staffing of utilization management nurses
- Following CMS approval of Syrenity for the ACCESS Model,
Syra Health is actively recruiting Accountable Care Organizations (ACOs) to utilize Syrenity, delivered with partner HealthSync, as part of their participation in the model.
Management Commentary
The results speak to the durability of what we're building. Through the first nine months of 2026, we generated net income of
We believe the best is still ahead. Our approval for Syrenity within the CMS ACCESS Model with our partner HealthSync is expected to become a consistent source of revenue over the next decade. With strong momentum across our business, we remain focused on delivering full-year profitability in 2026 and creating long-term value for our customers, the communities we serve, and our shareholders."
Q3 2026 Financial Results
Third quarter 2026 revenue rose 52% to
Healthcare workforce revenue increased 50% to
Gross profit margin widened by 1,340 basis points to 46.3% in the third quarter of 2026, up from 32.9% in the prior year period, driven by a favorable revenue mix and ongoing operating leverage.
The Company balanced disciplined cost management with targeted investment in growth. Salaries and benefits grew to
Operating activities provided
| BALANCE SHEETS | ||||||||
| | | | | | | | ||
| | | | | | | | ||
| | | 2026 | | | 2025 | | ||
| | | (Unaudited) | | | | | ||
| ASSETS | | | | | | | | |
| Current assets: | | | | | | | | |
| Cash and cash equivalents | | $ | 2,383,413 | | | $ | 1,614,733 | |
| Accounts receivable, net | | | 1,517,493 | | | | 918,374 | |
| Other current assets | | | 262,998 | | | | 205,423 | |
| Total current assets | | | 4,163,904 | | | | 2,738,530 | |
| | | | | | | | | |
| Property and equipment, net | | | 4,476 | | | | 6,986 | |
| Right-of-use asset | | | 57,010 | | | | 27,401 | |
| | | | | | | | | |
| Total assets | | $ | 4,225,390 | | | $ | 2,772,917 | |
| | | | | | | | | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | | | |
| | | | | | | | | |
| Current liabilities: | | | | | | | | |
| Accounts payable | | $ | 211,169 | | | $ | 247,520 | |
| Accounts payable, related party | | | 125,000 | | | | 72,000 | |
| Accrued expenses | | | 367,996 | | | | 194,821 | |
| Deferred revenue | | | 261,249 | | | | 16,611 | |
| Current portion of operating lease liability, related party | | | 57,010 | | | | 27,401 | |
| Notes payable | | | 179,272 | | | | 116,386 | |
| Total current liabilities | | | 1,201,696 | | | | 674,739 | |
| | | | | | | | | |
| Non-current portion of operating lease liability, related party | | | - | | | | - | |
| | | | | | | | | |
| Total liabilities | | | 1,201,696 | | | | 674,739 | |
| | | | | | | | | |
| Commitments and contingencies | | | | | | | | |
| | | | | | | | | |
| Stockholders' equity: | | | | | | | | |
| Preferred stock, | | | - | | | | - | |
| Class A common stock, | | | 13,850 | | | | 11,339 | |
| Convertible class B common stock, | | | 350 | | | | 600 | |
| Additional paid-in capital | | | 11,894,189 | | | | 11,806,765 | |
| Accumulated deficit | | | (8,884,695) | | | | (9,720,526) | |
| Total stockholders' equity | | | 3,023,694 | | | | 2,098,178 | |
| | | | | | | | | |
| Total liabilities and stockholders' equity | | $ | 4,225,390 | | | $ | 2,772,917 | |
| STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||||||
| | | | | | | | ||||||||||
| | | For the Three Months Ended | | | For the Nine Months Ended | | ||||||||||
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | | ||||
| | | | | | | | | | | | | | ||||
| Net revenues | | $ | 2,557,295 | | | $ | 1,687,971 | | | $ | 7,225,238 | | | $ | 5,491,944 | |
| Cost of services | | | 1,372,254 | | | | 1,133,430 | | | | 4,002,639 | | | | 3,595,352 | |
| Gross profit | | | 1,185,041 | | | | 554,541 | | | | 3,222,599 | | | | 1,896,592 | |
| | | | | | | | | | | | | | | | | |
| Operating expenses: | | | | | | | | | | | | | | | | |
| Salaries and benefits | | | 440,172 | | | | 336,390 | | | | 1,204,417 | | | | 1,169,951 | |
| Professional services | | | 175,295 | | | | 191,726 | | | | 500,455 | | | | 580,691 | |
| Research and development expenses | | | 46,716 | | | | 816 | | | | 100,988 | | | | 67,701 | |
| Selling, general and administrative | | | 222,141 | | | | 252,384 | | | | 671,673 | | | | 828,741 | |
| Depreciation | | | 715 | | | | 5,396 | | | | 2,510 | | | | 18,171 | |
| Total operating expenses | | | 885,039 | | | | 786,712 | | | | 2,480,043 | | | | 2,665,255 | |
| | | | | | | | | | | | | | | | | |
| Operating income (loss) | | | 300,002 | | | | (232,171) | | | | 742,556 | | | | (768,663) | |
| | | | | | | | | | | | | | | | | |
| Other income (expense): | | | | | | | | | | | | | | | | |
| Interest income | | | 1,008 | | | | 8,174 | | | | 54,354 | | | | 15,892 | |
| Interest expense | | | (1,353) | | | | (1,905) | | | | (6,032) | | | | (8,992) | |
| Total other income (expense) | | | (345) | | | | 6,269 | | | | 48,322 | | | | 6,900 | |
| | | | | | | | | | | | | | | | | |
| Income (loss) before income taxes | | | 299,657 | | | | (225,902) | | | | 790,878 | | | | (761,763) | |
| Benefit of (provision for) income taxes | | | 44,953 | | | | - | | | | 44,953 | | | | - | |
| Net income (loss) | | $ | 344,610 | | | $ | (225,902) | | | $ | 835,831 | | | $ | (761,763) | |
| | | | | | | | | | | | | | | | | |
| Weighted average common shares | | | 14,194,482 | | | | 11,939,169 | | | | 13,111,289 | | | | 11,823,089 | |
| Weighted average common shares | | | 15,142,247 | | | | 11,939,169 | | | | 14,059,054 | | | | 11,823,089 | |
| Net income (loss) per common share - | | $ | 0.02 | | | $ | (0.02) | | | $ | 0.06 | | | $ | (0.06) | |
|
| ||||||||
| | | | | |||||
| | | For the Nine Months Ended | | |||||
| | | | | |||||
| | | 2026 | | | 2025 | | ||
| CASH FLOWS FROM OPERATING ACTIVITIES | | | | | | | | |
| Net income (loss) | | $ | 835,831 | | | $ | (761,763) | |
| Adjustments to reconcile net income (loss) to net cash provided by | | | | | | | | |
| Depreciation | | | 2,511 | | | | 18,171 | |
| Common stock issued for services | | | - | | | | 2,586 | |
| Stock-based compensation | | | 89,685 | | | | 75,194 | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable | | | (599,119) | | | | (245,428) | |
| Other current assets | | | 211,654 | | | | 279,890 | |
| Right-of-use asset | | | 50,511 | | | | 89,621 | |
| Accounts payable | | | (36,352) | | | | 215,723 | |
| Accounts payable, related party | | | 53,000 | | | | 137,764 | |
| Deferred revenue | | | 244,638 | | | | 125,000 | |
| Accrued expenses | | | 173,175 | | | | (5,691) | |
| Operating lease liability | | | (50,511) | | | | (89,621) | |
| Net cash provided by operating activities | | | 975,023 | | | | (158,554) | |
| | | | | | | | | |
| CASH FLOWS FROM INVESTING ACTIVITIES | | | | | | | | |
| Purchase of property and equipment | | | - | | | | - | |
| Net cash used in investing activities | | | - | | | | - | |
| | | | | | | | | |
| CASH FLOWS FROM FINANCING ACTIVITIES | | | | | | | | |
| Proceeds from sale of common stock and exercise of warrants | | | - | | | | 14,800 | |
| Repayments on notes payable | | | (206,343) | | | | (275,106) | |
| Net cash used in financing activities | | | (206,343) | | | | (260,306) | |
| | | | | | | | | |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | | | 768,680 | | | | (418,860) | |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF | | | 1,614,733 | | | | 2,395,405 | |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | | $ | 2,383,413 | | | $ | 1,976,454 | |
| | | | | | | | | |
| SUPPLEMENTAL INFORMATION: | | | | | | | | |
| Interest paid | | $ | 6,032 | | | $ | 8,992 | |
| Income taxes paid | | $ | - | | | $ | - | |
| | | | | | | | | |
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | | | | | | | | |
| | | | | | | | | |
| Conversion of Class B common stock to Class A common stock | | $ | 2,500 | | | $ | 2,333 | |
| Cashless Exercise of Series B Warrants into Class A common | | $ | 11 | | | $ | - | |
| Recognition of right-of-use asset and lease liability | | $ | 80,120 | | | $ | - | |
| Amendment of right-of-use asset and lease liability | | $ | - | | | $ | 166,119 | |
| Prepaid asset financed with note payable | | $ | 269,229 | | | $ | 311,118 | |
Non-GAAP Financial Measures
In addition to financial results reported in accordance with accounting principles generally accepted in
| | | | | |
| | Nine Months Ended | | ||
| | | | | |
| | | | | |
| Net Income (Loss) | $ 835,831 | | $ (761,763) | |
| Interest expense | 6,032 | | 8,992 | |
| Depreciation expense | 2,510 | | 18,171 | |
| Provision for income taxes | (44,953) | | - | |
| Earnings before Interest, Taxes Depreciation and Amortization | $ 799,420 | | $ (734,600) | |
| | | | | |
| | Three Months Ended | | ||
| | | | | |
| | | | | |
| Net Income (Loss) | $ 344,610 | | $ (225,902) | |
| Interest expense | 1,353 | | 1,905 | |
| Depreciation expense | 715 | | 5,396 | |
| Provision for income taxes | (44,953) | | - | |
| Earnings before Interest, Taxes Depreciation and Amortization | $ 301,725 | | $ (218,601) | |
About
Discover our healthcare solutions at www.syrahealth.com and follow the Company on LinkedIn.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended
Contact
IR/PR Director
christined@syrahealth.com
463-345-5180
View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-delivers-third-consecutive-profitable-quarter-record-revenue-of-2-6-million-up-52-and-46-3-gross-margin-302927740.html
SOURCE